Introduction
The discovery and application of antimicrobial chemotherapy, particularly in the latter half of the 20th century, allowed control over most infectious diseases caused by bacteria and drastically reduced their associated mortality and morbidity. The emergence of bacterial resistance to antimicrobial agents began shortly after their introduction to clinical practice. 1 The level of resistance has developed rapidly and increasingly throughout the 1990s, so that today, many bacterial infections are caused by antibiotic-resistant strains.
Ironically, the driving forces for the development of antimicrobial resistance are antimicrobial agents themselves. Many non-pathogenic commensal bacterial species contain genes that confer resistance to particular antimicrobial agents. Bacteria have a high spontaneous mutation rate, a rapid generation time and the ability to acquire genetic material by both vertical and horizontal transmission. Therefore, during colonization or infection with a pathogenic bacterium, an antimicrobial-resistant subpopulation of the pathogen may develop due to mutation or the acquisition of genetic material. The presence of an antimicrobial agent to which the subpopulation is resistant can allow the subpopulation to predominate. The ability of a pathogen to cause an infection is also dependent on the infectious challenge. The combination of appropriate antimicrobial therapy and the immune response is usually sufficient to eliminate the pathogen and the resistant subpopulation. Hence, inadequate or inappropriate therapy and/or immune response can contribute to the development of antimicrobial resistance.
The dissemination of resistant clones is complicated and dependent on numerous biological, physical and socioeconomic factors. Hence, the progression of a particular form of antimicrobial resistance is unpredictable. Because of the multifactorial nature of resistance development, it is not entirely surprising that the level and genetic basis of resistance can vary widely between continents, regions, countries, cities, institutions and communities. To add to the therapeutic dilemma faced by clinicians, laboratory isolation of the causative agent and determination of its antimicrobial susceptibility pattern are not always possible, and rarely of immediate use, during the therapeutic decision-making process. Because culture results are not available at the time of therapeutic decision-making, treatment success or failure depends upon up-to-date, accurate and local information on the bacterial aetiology of the infection concerned, and the prevalence of antimicrobial resistance amongst those pathogens. Hence, the practical need for surveillance studies is shown at this most critical point. Patient mortality or morbidity can be reduced with the availability of reliable and timely information. Surveillance data also provide vital information for research into the spread and cause of antimicrobial resistance, such as the impact of antibiotic consumption on the development of resistance.
In this paper, the need for surveillance studies as outlined above will be discussed in more detail from the perspective of respiratory tract infections (RTIs). The components of an RTI surveillance study that make it effective and suitable for the desired outcomes will be examined, and previously reported RTI surveillance studies will be reviewed critically using these guidelines. PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is an RTI surveillance study designed to fulfil these requirements. The design of PROTEKT will also be a focus of this paper whilst the results from the first year of PROTEKT will be discussed in other papers in this supplement.
The need for surveillance in RTIs
The overall purpose of surveillance studies is: (i) to determine the level of resistance in a particular geographical region to guide empirical therapy; and (ii) to monitor changes in the level of resistance and make this information available to therapeutic decision-makers in a timeframe that maximizes appropriate antimicrobial agent prescription. 2 Surveillance is also necessary to provide information on the mechanisms of resistance, and how such resistance develops, persists in a population and then spreads to other populations. This information is critical for developing and monitoring intervention programmes (such as formulary and prescribing changes, and infection control procedures) to minimize the spread of resistance.
Acute RTIs are the third leading cause of morbidity and mortality worldwide. 3 The most common bacterial causes of community-acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease, otitis media and sinusitis are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. [4] [5] [6] [7] The so-called 'atypical' bacteria (Chlamydophila (Chlamydia) pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila) also play a role. Streptococcus pyogenes is the major bacterial pathogen in tonsillitis/pharyngitis.
Until the early 1990s, penicillin G was the best therapeutic option for the treatment of pneumococcal infections. Reports of an increasing prevalence of penicillin G resistance in pneumococci introduced uncertainty into the choice of empirical therapy. 8 The emergence of multi-resistant pneumococci further complicated the therapeutic decision-making process. 9 Although it has been difficult to determine the consequence of antimicrobial resistance in pneumococci on patient morbidity and mortality, a high correlation has been observed with high-level β-lactam resistance. In one study, when deaths during the first 4 hospital days were excluded, mortality was significantly associated with penicillin MICs of 4 mg/L or higher and cefotaxime MICs of 2 mg/L or higher. 10 One of the most compelling arguments to support surveillance studies, therefore, is to provide data to determine antimicrobial resistance patterns that facilitate the development of optimal empirical therapeutic guidelines based on outcome analyses. Of course, the need for reliable clinical data underscores the value of interpreting surveillance data and illustrates one of the major limitations of surveillance studies to date.
Although surveillance data for antimicrobial resistance indicate that levels of resistance for H. influenzae and M. catarrhalis are relatively static, 4-6 history compels us not to be complacent. Resistance development is multifactorial in nature and cannot be predicted with any accuracy. The rapid development of β-lactam resistance in pneumococci was not predicted and the corollary to this is that H. influenzae and M. catarrhalis could follow a similar path, with resistance to other classes of antimicrobials evolving unexpectedly. In addition, antimicrobial resistance in pneumococci can vary widely by city, region, country and continent. The status quo is not an argument to discontinue surveillance efforts. The overall unpredictable nature of resistance development and the inability to extrapolate data from one location to another are compelling arguments for continued surveillance.
To summarize, diagnosis of the causative agent in community-acquired RTIs (CARTIs) is often unreliable and usually slow. The choice of antimicrobial therapy is, therefore, most frequently empirical. The prevalence of antimicrobial resistance in S. pneumoniae is unpredictable and varies widely geographically. By comparison, the prevalence of antimicrobial resistance in other pathogens has been more stable but could change rapidly. Surveillance studies of the prevalence of resistance in the key pathogens are necessary to ensure rational prescribing.
What makes a good surveillance study?
Surveillance has been described as: 'the ongoing and systematic collection, analysis, and interpretation of health data in the process of describing and monitoring a health event'. 11 This statement is an accurate general description of an effective surveillance study. An effective surveillance study must provide chronological data for comparison (ongoing); the data must be collected, analysed and interpreted in a manner that is consistent and comparable between different centres, geographical regions and studies; and the data must accurately describe and monitor a health event (the impact of anti-microbial resistance on morbidity and mortality) in a timely fashion to allow appropriate interventions to be introduced to reduce adverse health outcomes.
Antimicrobial resistance surveillance programmes can be used for planning, implementing and evaluating any intervention or programme (such as a new therapeutic regime or infection control procedure). As described above, the data obtained from a surveillance study have two general purposes: (i) to help determine the need for a new intervention or programme; and (ii) to monitor the effectiveness of an intervention or programme. 11 The requirements of an effective antimicrobial resistance programme are listed in Table 1 .
Antimicrobial resistance is a global problem. Antimicrobial resistance that develops in one country can disseminate throughout the world in an extremely short time, e.g. the highly resistant serotype 23F Spanish clone of S. pneumoniae. The World Health Organization 3 has suggested that any strategy to investigate and reduce antimicrobial resistance should include research based in developing as well as developed countries. 12 It is clear that many multi-resistant bacteria are not constrained by geographical boundaries. An important aspect of any plan designed to monitor antimicrobial resistance is the need to ignore such boundaries and include a wide geographical distribution of centres and isolates.
The comparability of data between studies is extremely important to monitor accurately base levels of resistance and shifts in antimicrobial susceptibility patterns. This can best be achieved through the use of standardized methods, centralized laboratory testing and strict laboratory quality control systems. 13 Recently in the USA, an interagency taskforce (with the major co-chairs being the CDC, the FDA and the NIH) produced a health action plan to combat antimicrobial resistance. 14 One key priority identified was the development of standardized laboratory methodologies that allow susceptibility test results to be compared between different studies and across different geographical regions.
Another key priority identified by the taskforce was to develop standards for reporting quantitative resistance so that levels of decreased susceptibility could be assessed, rather than examining simple qualitative parameters (susceptible, intermediate, resistant). The analysis of subtle shifts in MIC data obtained from longitudinal surveillance studies is a powerful tool in predicting the development of antimicrobial resistance, and hence quantitative MIC determination is a key parameter when evaluating the usefulness of a surveillance study.
Although molecular epidemiological investigations to determine clonal relationships of pathogens are used in a current longitudinal global surveillance study (SENTRY), to date no global longitudinal RTI surveillance study has included data to determine the distribution of antimicrobial resistance genes. This information is a crucial component in the research into the development and dissemination of antimicrobial resistance. The WHO recently identified the lack of information concerning microbial genetics and ecology in antimicrobial-resistant bacteria as a gap in current knowledge Table 1 . Desirable components of a global RTI surveillance programme
Programme design
Longitudinal to monitor the evolution of resistance trends. Comprehensive local, regional, and national representation. Independence from corporate strategies. Quality assurance system for total management of programme.
Methodology
Well-defined specimen collection, storage and transportation protocols. Standardized testing methods that are internationally recognized (e.g. NCCLS). Central laboratory testing. Wide range of antimicrobials tested with quantitative determination. Determination of resistance mechanisms. Assessment of antibiotic usage with level of resistance. Quality control programme for laboratory testing and data analysis.
Clinical
Clinical guidelines for inclusion of patients and specimens. Collection and integration of clinical and demographic data. Guidelines for interpretation of surveillance data.
Dissemination of surveillance data
Easy access to up-to-date data-preferably internet access with the ability to download data on to hand-held computers. Ability for user to perform custom analyses. and hence a key research need. Ideally, therefore, a good surveillance study should address these issues.
The collection of accurate clinical and demographic data has been a major limitation of surveillance studies to date. Rules for patient recruitment need to be improved to reduce bias and error caused by geographical and sample population variation. 13 For example, a recent study in Germany demonstrated that surveillance data collected from only one or two centres in a country may not reflect the true pattern of resistance at a local level in that country. 15 Bacterial respiratory tract pathogens, such as S. pneumoniae, H. influenzae and M. catarrhalis, are also present as commensal organisms in a large proportion of healthy subjects. Clinical information is very difficult to obtain and such information is critical in the assessment for inclusion of an isolate as a pathogen.
The next section describes the PROTEKT study, which has been designed to address many of the limitations of other ongoing longitudinal global RTI surveillance studies.
The PROTEKT study

Study objectives
The PROTEKT study is a longitudinal, global, multicentre surveillance study. The primary objectives of PROTEKT are: (i) to examine the in vitro susceptibility to telithromycin compared with other currently prescribed antibacterials and support the rationale for the use of the compound in a global environment; and (ii) to document the prevalence of resistance phenotypes and genotypes, and the activity of a range of antimicrobial agents, including telithromycin, against such strains.
A secondary objective is to determine the activity of telithromycin against CARTI isolates, in relation to the frequency of prescribing, in the regions where the study is conducted.
Study design
Bacterial isolates are collected from patients with one of the following six types of CARTIs: pneumonia, acute bacterial exacerbation of chronic bronchitis, acute exacerbation of chronic obstructive airways disease, sinusitis, tonsillitis/ pharyngitis and otitis media. Each centre in the study is asked to collect the minimum number of each species designated in Table 2 . A total of 69 centres from 25 countries were enrolled in the first year of PROTEKT (1999-2000): Canada (7), USA (8), Mexico (4), Brazil (7), Argentina (2), Germany (7), the Netherlands (1), Sweden (1), UK (2), Eire (1), Belgium (1), France (4), Portugal (2), Spain (2), Switzerland (2), Italy (2), Austria (1), Turkey (1), Hungary (1), Poland (1), Hong Kong (1), Japan (6), South Korea (2), Australia (2) and Indonesia (1). The current total exceeds 100 centres. Antimicrobial agents tested are listed in Table 3 .
Specimens are acceptable if they were isolated from patients diagnosed with one of the six specified CARTIs or from hospitalized patients within 48 h of admission. Acceptable sources for isolates are blood cultures, sputum cultures determined to be acceptable based on the number of white blood cells and epithelial cells observed in a Gram stain, bronchoalveolar lavage fluid, pus from middle ear fluid, ear cultures (from specimens obtained by tympanocentesis), nasopharyngeal swab or aspirate cultures, sinus aspirate cultures and throat cultures (S. pyogenes only). Isolates are excluded from patients acquiring nosocomial lower RTI, patients with cystic fibrosis, and sputum samples with a poor Gram stain. Duplicate or multiple isolates from the same patient are also excluded. The following demographic information is collected for each patient: collection date; collection centre and country; infection type; specimen source; age; in/outpatient status; and gender.
Study protocols
Each centre is given a detailed study protocol to provide guidance in the collection and processing of specimens, and the storage and transportation of isolates.
Storage and transportation of isolates
Isolates are stored as a heavy suspension in horse serum, skimmed milk or Microbank cryovials (Pro-Lab Diagnostics, South Wirral, UK), at -20°C (preferably at -70°C) at the collecting centre. When a batch of sufficient size (at least 50 isolates) is obtained, the isolates are transferred to the central testing laboratory. After identification is confirmed, isolates are stored at -70°C as a heavy suspension in horse serum. Sub-cultures were made by touching a red-hot loop onto the surface of the frozen suspension and spreading the thawed culture onto the surface of a suitable agar growth medium. This procedure minimizes the risk of phenotypic variation caused by repeated freeze-thaw cycles.
Laboratory testing methodology and quality control
The identification of all isolates is confirmed at a central reference laboratory (GR Micro Ltd, London, UK), using Gram stain and colony morphology, and the following tests:
(i) S. pneumoniae-catalase reaction, optochin susceptibility and bile solubility; (ii) H. influenzae-X (haemin), V (nicotinamide adenine dinucleotide) and combined X+V dependency; (iii) M. catarrhalis-oxidase reaction and hydrolysis of tributyrin; (iv) S. pyogenes-bacitracin susceptibility, L-pyrrolidonyl-β-naphthylamide (PYR) hydrolysis, serological grouping.
MICs are determined using the broth (cation-adjusted Mueller-Hinton) microdilution method of the National Committee for Clinical Laboratory Standards (NCCLS) 16 with an inoculum of 3-7 × 10 4 cfu in 100 µL medium. Trays containing the lyophilized antimicrobial, and the Mueller-Hinton broth, are obtained commercially (Sensititre, Trek Diagnostic Systems Ltd, East Grinstead, UK). The medium is supplemented with water-lysed horse blood (final concentration 2% v/v) and nicotinamide adenine dinucleotide (final concentration 10 mg/L) for isolates of S. pneumoniae and S. pyogenes. For H. influenzae, the Mueller-Hinton broth is replaced by Haemophilus test medium. After incubation of sealed plates in air for 20-22 h at 35°C, MIC endpoints are read as the lowest concentrations of antimicrobial that totally inhibit macroscopically visible growth of the inoculum. Interpretation of test results is based on NCCLS interpretative criteria, 17 chosen because globally, they are the most commonly applied standards and guidelines for susceptibility breakpoints.
The β-Lactamase activity is detected using the chromogenic cephalosporin (nitrocefin) test (Oxoid, Basingstoke, UK). Macrolide resistance mechanisms are determined using a multiplex polymerase chain reaction (PCR) assay with microwell-format probe hybridization, as previously described. 18 
Data analysis and availability
Raw MIC data from the Sensititre assay system are transmitted electronically to Micron Research (Upwell, UK) and, once checked and validated, loaded into the SAS-based SILK (Solutions in Internet Linked Knowledge) database. The SILK database is available to registered users via the internet (www.protekt.org). Listings, summary tabulations, MIC distributions, susceptibility profiles, cross-resistance examination and geographical distribution are accessible using the SILK program and searches can be performed by location and/or pathogen.
A comparison of the key features of ongoing longitudinal global RTI surveillance studies is given in Table 4 .
Discussion
As shown in Table 1 , there are many desired components for an effective RTI surveillance study. As can be seen in Table 4 , the Alexander Project and SENTRY are both well-designed studies that fulfil many of these requirements and have provided, and still provide, invaluable data on global antimicrobial resistance. As previously discussed, the major drawbacks of the largest current RTI studies (the Alexander Project and the RTI component of SENTRY) are the limited amount of clinical and demographic data, incomplete resistance mechanism determination, and the limited availability of up-to-date data in an easily accessible format tailor-made to the user's knowledge and professional profile. PROTEKT was specifically designed to address these requirements.
Significant clinical and demographic data have been included. The integrity of the clinical and demographic data is controlled in a number of ways: (i) by limiting the amount of data investigators need to collect to fulfil the objectives of the study, hence minimizing non-compliance due to the frustration of collecting large amounts of unnecessary data; (ii) the availability of a detailed study protocol; (iii) simplified recording, transportation and storage of data; and (iv) quality assurance protocols that maintain investigator and patient confidentiality.
Molecular epidemiological techniques and resistance mechanism determinations, as used in PROTEKT, allow assessment for clonality among isolates. 19 Another important inclusion in PROTEKT is the molecular determination of macrolide resistance mechanisms in all macrolide-resistant S. pneumoniae and S. pyogenes. This is a first for large-scale respiratory studies and the findings for PROTEKT 1999-2000 are reported in this supplement. 20 This information will form a basis for the longitudinal analysis of shifts in resistance mechanisms in PROTEKT and help to determine the dissemination of antimicrobial resistance. In addition, new mechanisms of resistance were found for 19 S. pneumoniae isolates in PROTEKT 1999-2000. 21 Monitoring the spread of these new mechanisms in subsequent PROTEKT years will help to determine the evolution of antimicrobial resistance. Molecular epidemiological techniques are also used in PROTEKT to investigate interesting 'pockets' of resistance. For example, fluoroquinolone-resistant S. pneumoniae from Hong Kong were found to be clonal by using pulsed-field gel electrophoresis, multilocus-sequence typing and serotyping. 22 Ease of access to current data was addressed in the Alexander Project by introducing a searchable database to registered users on the internet (www.alexander-network.com). A webbased searchable database is also available in PROTEKT, with the added advantage of being able to download data to a hand-held computer to serve as a 'bedside' guide to empirical therapy based on local antimicrobial resistance profiles.
In summary, the PROTEKT study has included all of the features of its successful counterparts (the Alexander Project and SENTRY) whilst attempting to address the limitations of these studies. In 2002, PROTEKT has expanded into more than 100 centres in 26 countries, included the molecular determination of β-lactamase type for H. influenzae, the determination of resistance mechanisms in quinolone-resistant and telithromycin-resistant S. pneumoniae and S. pyogenes, and enhancements to the availability of data through www.protekt.org. In addition, new initiatives have begun to give increased local representation in key countries, e.g. the USA, where a similar study comprising more than 200 centres is underway. PROTEKT promises to be an extremely useful tool in providing clinicians and decision-makers treating CARTIs with the most recent antimicrobial resistance data at international, national and local levels.
